#Gate 2025 Semi-Year Community Gala# voting is in progress! 🔥
Gate Square TOP 40 Creator Leaderboard is out
🙌 Vote to support your favorite creators: www.gate.com/activities/community-vote
Earn Votes by completing daily [Square] tasks. 30 delivered Votes = 1 lucky draw chance!
🎁 Win prizes like iPhone 16 Pro Max, Golden Bull Sculpture, Futures Voucher, and hot tokens.
The more you support, the higher your chances!
Vote to support creators now and win big!
https://www.gate.com/announcements/article/45974
A drug from AstraZeneca failed to meet the primary goals of the study.
Jin10 reported on July 16 that AstraZeneca said on Wednesday that its experimental drug Anselamimab did not meet the primary endpoint of late-stage studies for the treatment of AL amyloidosis. AL amyloidosis is a rare disease that causes an increase in protein deposits in the body, leading to significant organ damage.